A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

The company hopes to stand out with Diabegone, a diabetes treatment that lasts longer than competing drugs from companies ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

In 2024, 26.5% of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables.

Tennis legend Serena Williams has sparked conversations around fitness and health after reports of her weight loss journey ...

Aon has invested in eMed Population Health, a provider of GLP-1 programs, to expand employer-sponsored access to GLP-1 ...

For decades, fitness influencers and athletes swore by “clean eating” and intense workouts as the ultimate path to weight loss and peak performance. But Serena Williams’s revelation signals a ...